Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast
Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast
复制标题
DOI：
10.1111/j.1600-0463.2006.apm_434.x
复制
发表时间：
2006-10-01
期刊：
影响因子：
2.8
通讯作者：
Sakamoto, Goi
中科院分区：
文献类型：
--
作者：
Honma, Naoko;Takubo, Kaiyo;Sakamoto, Goi
总囊性疾病液蛋白-15 （GCDFP-15）是常用的大汗液标志物；然而，最近发现其表达在浸润性、较大的或转移性乳腺大汗腺癌中减少。在乳腺中，单克隆抗体（MAb） B72.3已被报道可作为大汗液标记物，尽管其用于此目的的频率远低于GCDFP-15。为了寻找更一致的大汗液标志物，我们在不同阶段的大汗液癌中检测了MAb B72.3的免疫反应性，并与GCDFP-15进行了比较。51例大汗腺癌中47例（92%）和62例普通癌中9例（15%）为MAb B72.3阳性，51例大汗腺癌中39例（76%）和62例普通癌中13例（21%）为GCDFP-15阳性。因此，MAb B72.3的敏感性和特异性都更高。此外，与GCDFP-15不同，MAb B72.3与浸润状态、肿瘤大小或转移状态无关。MAb b72.3免疫反应性与gcdfp -15表达无相关性。MAb B72.3与GCDFP-15联合使用有助于确认大泌腺癌的诊断，特别是晚期肿瘤，只有2例MAb B72.3和GCDFP-15均阴性。这两例是否应与普通大汗腺癌鉴别仍有待研究。
Gross cystic disease fluid protein-15 (GCDFP-15) is a commonly used apocrine marker; however, its expression was recently found to decrease in infiltrating, larger, or metastasizing apocrine carcinomas of the breast. In the breast, monoclonal antibody (MAb) B72.3 has been reported to be useful as an apocrine marker although it is used for that purpose much less frequently than GCDFP-15. In the search for a more consistent apocrine marker, immunoreactivity for MAb B72.3 was examined in apocrine carcinomas at different stages and compared with GCDFP-15. 47 of 51 apocrine carcinomas (92%) and 9 of 62 ordinary carcinomas (15%) were MAb B72.3 positive, while 39 of 51 apocrine carcinomas (76%) and 13 of 62 ordinary carcinomas (21%) were GCDFP-15 positive. Thus, both sensitivity and specificity were higher for MAb B72.3. Furthermore, unlike GCDFP-15, MAb B72.3 exhibited positivity irrespective of infiltrating status, tumor size, or metastatic status. There was no correlation between MAb B72.3-immunoreactivity and GCDFP-15-expression. The combined usage of MAb B72.3 with GCDFP-15 was useful to confirm the diagnosis of apocrine carcinoma, especially for advanced tumors, with only two cases being negative for both MAb B72.3 and GCDFP-15. Whether these two cases should be differentiated from ordinary apocrine carcinomas remains to be investigated.